A phase 3 clinical trial (ACROINNOVA 1) in 72 patients with acromegaly who had previously demonstrated biochemical control on depot SRL monotherapy found superior biochemical control with CAM2029 compared with placebo (IGF-I ≤ ULN; 72.2% vs. 37.5%, p = 0.0018) and a safety profile consistent with SOC [52]. The gene discussed is IGF1; the disease is acromegaly.